MA30039B1 - Nouveaux derives de furopyrimidines a substitution acyclique et leur utilisation pour traiter des maladies cardiovasculaires - Google Patents

Nouveaux derives de furopyrimidines a substitution acyclique et leur utilisation pour traiter des maladies cardiovasculaires

Info

Publication number
MA30039B1
MA30039B1 MA31016A MA31016A MA30039B1 MA 30039 B1 MA30039 B1 MA 30039B1 MA 31016 A MA31016 A MA 31016A MA 31016 A MA31016 A MA 31016A MA 30039 B1 MA30039 B1 MA 30039B1
Authority
MA
Morocco
Prior art keywords
cardiovascular diseases
treating cardiovascular
acyclic substituted
novel acyclic
furopyrimidine derivatives
Prior art date
Application number
MA31016A
Other languages
English (en)
Inventor
Thomas Lampe
Eva-Maria Becker
Raimund Kast
Hartmut Beck
Mario Jeske
Joachim Schuhmacher
Friederike Stoll
Martina Klein
Metin Akbaba
Andreas Knorr
Johannes-Peter Stasch
Lars Baerfacker
Alexander Hillisch
Gunter Karig
Mark Meininghaus
Karl-Heinz Schlemmer
Rudolf Schohe-Loop
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA30039B1 publication Critical patent/MA30039B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Nouveaux dérivés de furopyrimidine substitués de manière acyclique, et leurs applications La présente demande concerne des nouveaux dérivés de furopyrimidine substitués de manière acyclique, des procédés de production de ceux-ci, et leurs applications pour le traitement et/ou la prophylaxie de maladies, et leurs applications pour la production de produits médicinaux, pour le traitement et/ou la prophylaxie de maladies, en particulier, pour le traitement et/ou la prophylaxie de maladies cardiovasculaires.
MA31016A 2005-12-21 2008-06-11 Nouveaux derives de furopyrimidines a substitution acyclique et leur utilisation pour traiter des maladies cardiovasculaires MA30039B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005061170A DE102005061170A1 (de) 2005-12-21 2005-12-21 Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung

Publications (1)

Publication Number Publication Date
MA30039B1 true MA30039B1 (fr) 2008-12-01

Family

ID=37876878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31016A MA30039B1 (fr) 2005-12-21 2008-06-11 Nouveaux derives de furopyrimidines a substitution acyclique et leur utilisation pour traiter des maladies cardiovasculaires

Country Status (31)

Country Link
US (1) US8183246B2 (fr)
EP (1) EP1966217B1 (fr)
JP (1) JP5254032B2 (fr)
KR (1) KR101429777B1 (fr)
CN (1) CN101384603B (fr)
AR (1) AR058108A1 (fr)
AU (1) AU2006334856B2 (fr)
BR (1) BRPI0620317A2 (fr)
CA (1) CA2633701C (fr)
CR (1) CR10092A (fr)
DE (1) DE102005061170A1 (fr)
DK (1) DK1966217T3 (fr)
DO (1) DOP2006000280A (fr)
EC (1) ECSP088569A (fr)
ES (1) ES2418855T3 (fr)
GT (1) GT200800117A (fr)
IL (1) IL192062A0 (fr)
MA (1) MA30039B1 (fr)
NO (1) NO20082986L (fr)
NZ (1) NZ569214A (fr)
PE (1) PE20071168A1 (fr)
PL (1) PL1966217T3 (fr)
PT (1) PT1966217E (fr)
RU (1) RU2454419C2 (fr)
SV (1) SV2009002953A (fr)
TN (1) TNSN08279A1 (fr)
TW (1) TWI405764B (fr)
UA (1) UA94080C2 (fr)
UY (1) UY30046A1 (fr)
WO (1) WO2007079862A1 (fr)
ZA (1) ZA200805385B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007019691A1 (de) * 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007027799A1 (de) * 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte Furopyrimidine und ihre Verwendung
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
DE102007054786A1 (de) * 2007-11-16 2009-05-20 Bayer Healthcare Ag Trisubstituierte Furopyrimidine und ihre Verwendung
WO2013168759A1 (fr) 2012-05-10 2013-11-14 武田薬品工業株式会社 Composé cyclique aromatique
US9505772B2 (en) 2012-05-10 2016-11-29 Takeda Pharmaceutical Company Limited Aromatic ring compound
EP3562828B1 (fr) 2016-12-28 2026-03-18 Dart Neuroscience LLC Composés pyrazolopyrimidinone substitués en tant qu'inhibiteurs de pde2
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
ES3065954T3 (en) * 2019-05-13 2026-05-08 Relay Therapeutics Inc Fgfr inhibitors and methods of use thereof
KR102094337B1 (ko) 2019-10-01 2020-03-27 안문호 금속이물질 제거장치
TWI924727B (zh) 2020-11-18 2026-05-11 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577420A (en) 1968-01-05 1971-05-04 Pfizer Certain 4-aminofuro(2,3-d)pyrimidines
ES2219033T3 (es) 1998-07-22 2004-11-16 Daiichi Suntory Pharma Co., Ltd. Inhibidores de nf-kappa b que contienen derivados de indano como ingrediente activo.
HK1045306A1 (zh) 1999-06-03 2002-11-22 Abbott Laboratories 抑制细胞黏附的抗炎化合物
WO2001021206A1 (fr) 1999-09-17 2001-03-29 Suntory Limited MOYENS DE PREVENTION OU REMEDES CONTRE LA MYOCARDITE, LA CARDIOMYOPATHIE DILATEE ET L'INSUFFISANCE CARDIAQUE CONTENANT DES INHIBITEURS NF-λB EN TANT QU'INGREDIENT ACTIF
CA2449188A1 (fr) 2001-05-14 2002-11-21 Novartis Ag Oxazolopyrimidines et furopyrimidines et utilisation dans des agents pharmaceutiques contre les tumeurs
DE10141212A1 (de) 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
AU2002333524A1 (en) 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
US20030225098A1 (en) * 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
CA2568304A1 (fr) 2004-06-10 2005-12-22 Xention Discovery Limited Composes de furanopyrimidine efficaces comme inhibiteurs des canaux potassiques
JP2008505084A (ja) * 2004-06-29 2008-02-21 アムゲン インコーポレイティッド フラノピリミジン

Also Published As

Publication number Publication date
CN101384603B (zh) 2012-08-01
GT200800117A (es) 2009-12-16
EP1966217B1 (fr) 2013-05-08
RU2454419C2 (ru) 2012-06-27
RU2008129363A (ru) 2010-01-27
DK1966217T3 (da) 2013-08-05
AU2006334856B2 (en) 2013-04-04
KR20080081323A (ko) 2008-09-09
AU2006334856A1 (en) 2007-07-19
NO20082986L (no) 2008-07-02
TNSN08279A1 (en) 2009-10-30
PT1966217E (pt) 2013-07-12
AR058108A1 (es) 2008-01-23
CR10092A (es) 2008-10-08
DOP2006000280A (es) 2007-07-31
ECSP088569A (es) 2008-08-29
JP2009520713A (ja) 2009-05-28
UY30046A1 (es) 2007-07-31
EP1966217A1 (fr) 2008-09-10
PL1966217T3 (pl) 2013-09-30
PE20071168A1 (es) 2008-02-07
SV2009002953A (es) 2009-04-28
CN101384603A (zh) 2009-03-11
TWI405764B (zh) 2013-08-21
ES2418855T3 (es) 2013-08-16
BRPI0620317A2 (pt) 2011-11-08
JP5254032B2 (ja) 2013-08-07
ZA200805385B (en) 2009-10-28
HK1130054A1 (en) 2009-12-18
CA2633701A1 (fr) 2007-07-19
US20090318475A1 (en) 2009-12-24
UA94080C2 (ru) 2011-04-11
TW200745132A (en) 2007-12-16
DE102005061170A1 (de) 2007-07-05
WO2007079862A1 (fr) 2007-07-19
IL192062A0 (en) 2008-12-29
KR101429777B1 (ko) 2014-08-19
NZ569214A (en) 2011-07-29
CA2633701C (fr) 2014-05-27
US8183246B2 (en) 2012-05-22

Similar Documents

Publication Publication Date Title
DE502005006149D1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
JO3018B1 (ar) مُركبات 4- أريل- 1 , 4 – ثنائي هيدرو -1 , 6- نافثيريدين أميد amides مُستبدلة وإستعمالها
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA42376A (fr) Dérivés d'oxopyridine substitués
MA44851B1 (fr) Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations
WO2009068214A3 (fr) Pipéridines à substitution hétéroaryl
BRPI0410454A (pt) composições e compostos imunossupressores
TNSN05294A1 (en) Immunosuppressant compounds and compositions
MXPA05012461A (es) Compuestos y composiciones inmunosupresores.
TW200736213A (en) Dicarboxylic acid derivatives and their use
ATE453642T1 (de) Substituierte phenylaminopyrimidine
ATE523510T1 (de) Substituierte 4-aryl-1,4-dihydro-1,6- naphthyridine und ihre verwendung
TNSN08279A1 (en) Bayer healthcare ag
MY150931A (en) Substituted oxazolidinones and their use
DE502007006625D1 (de) 3-cyano-5-thiazaheteroaryl-dihydropyridine und ihrnkungen
MA33290B1 (fr) Pipéridines substituées
MX2007013084A (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion.
GEP20135733B (en) Novel diazeniumdiolate derivatives, their preparation method and pharmaceutical compositions containing them
ATE475651T1 (de) Aryl-substituierte heterozyklen und ihre verwendung
MA33291B1 (fr) Pipéridines substituées
EA200701648A1 (ru) Замещённые пирролы и имидазолы, содержащие их композиции, способ получения и применение
MX2023005875A (es) Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
ATE420089T1 (de) Substituierte azachinazoline mit antiviraler wirkung
FR2887549B1 (fr) Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation